Urol. praxi, 2014; 15(3): 108-114

Overview of the current pharmacotherapy of LUTS

MUDr.Vladimír Giblo, MUDr.Miroslav Louda, Ph.D., MUDr.Jaroslav Pacovský, Ph.D.
Urologická klinika FN a LF UK Hradec Králové

Low urinary tract symptoms (LUTS) present age-related disease with important impact on the quality of life. Therapy of LUTS has been

dramatically changed in the last fiteen years. The most frequently used therapy is the pharmacotherapy at present. This paper describes

current possible pharmacological treatment, its effectivity and side effects.

Keywords: LUTS (lower urinary tract symptoms), lower urinary tract symptoms, overactive bladder, benign prostatic hyperplasia

Published: July 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Giblo V, Louda M, Pacovský J. Overview of the current pharmacotherapy of LUTS. Urol. praxi. 2014;15(3):108-114.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hora M. Fytopreparáty v léčbě BHP. Urol List 2004; 4: 42-45.
    2. Veselský Z. Pygeum africanum v kauzální terapii benigní hyperplazie prostaty. JAMA-CS, 8 (4), 2000, 326.
    3. Fjellestad-Paulsen A, Höglund P, Lundin S, et al. Pharmacokinetics of 1deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol 1993; 38 (2): 177-182. Go to original source... Go to PubMed...
    4. Rembratt A, Graugaard-Jensen C, Senderovitz T, et al. Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. Eur J Clin Pharmacol 2004; 60(6): 397-402. Go to original source... Go to PubMed...
    5. Hvistendahl GM, Riis A, Norgaard JP, et al. The pharmacokinetics of 400 ?g of oral desmopressin in elderly patients with nocturia, and the correlation between the absorption of desmopressin and clinical effect. BJU Int 2005; 95(6): 804-809. Go to original source... Go to PubMed...
    6. Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol. 2004 Sep; 172(3): 1021-1025. Go to original source... Go to PubMed...
    7. Lepor H, Shapiro E. Characterisation of alpha1 adrenergic receptors in human benign prostatic hyperplasia. J Urol 1984, 132: 1226-1229. Go to original source... Go to PubMed...
    8. Shapiro E, Lepor H. Alpha 2adrenergic receptors in hyperplastic human prostate: identification and characterization using/3H/rauwolscine. J Urol 1986, 135: 1038-1043. Go to original source... Go to PubMed...
    9. Caine M, Raz S, Ziegler M. Adrenergic a cholinergic receptors in the human prostatic capsule and bladder neck. Br J Urol 1975, 47: 193-202. Go to original source... Go to PubMed...
    10. Caine M. The present role of alpha adrenergic blockers in the treatment of benign prostatic hyperplasia. J Urol 1986, 136: 1-4. Go to original source... Go to PubMed...
    11. Marberger M, Harkaway R, de la Rosette J. Optimizing the medical management of benign prostatic hyperplasia. Eur Urol 2004; 45: 411-419. Go to original source... Go to PubMed...
    12. Navrátil P. Uroselektivita alfuzosinu při léčbě pacientů se symptomy BPH. Čes Urol 2001; 2: 4-8.
    13. MacDonald JD, Roehrborn CG, Bautista OM, et al. Afluzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology 2005; 66(4): 780-788. Go to original source... Go to PubMed...
    14. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha 1adrenoreceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Eur Urol 1999; 36: 1-13. Go to original source... Go to PubMed...
    15. Gormley GJ, Stoner E, Bruskewitz RC. The effect of finasteride in men with benign prostate hyperplasia. The Finasteride Study Group (see Comments). N Engl J Med 1992; 327: 1185-1191. Go to original source... Go to PubMed...
    16. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175(5): 999-1004 (Level 1b). Go to original source... Go to PubMed...
    17. Kaplan SA, Roehrborn CG, Chancellor M, et al. Extendedrelease tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int 2008; 102(9): 1133-1139 (Level 1b). Go to original source... Go to PubMed...
    18. Roehrborn CG, Kaplan SA, Kraus SR, et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 2008; 72(5): 1061-1067 (Level 1b). Go to original source... Go to PubMed...
    19. Galeo BJ, Galee MA. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men. Ann Pharmacother 2008; 42: 111-115. Go to original source... Go to PubMed...
    20. Ückert S, Küthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nukleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001; 166(6): 2484-2490. (Level 2b). http://www.ncbi.nlm.nih.gov/pubmed/11696815. Go to original source... Go to PubMed...
    21. Ückert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P. Immunohistochemical distribution of cAMP - and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 2006; 49(4): 740-745. (Level 2b). Go to original source... Go to PubMed...
    22. Andersson KE, Persson K. Nitric oxide synthase and the lower urinary tract: possible implications for physiology and pathophysiology. Scand J Urol Nephrol Suppl 1995; 175: 43-53.
    23. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on košer urinary tract symp toms in men with erectile dysfunction. J Sex Med 2006; 3: 662-667. Go to original source... Go to PubMed...
    24. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int 2002; 90(9): 836-839. Go to original source... Go to PubMed...
    25. Roehrborn CG, Kaminetsky JC, Auerbach SM, et al. Changes in peak urinary fl ow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 2010; 105(4): 502-507. (Level 1b). Go to original source... Go to PubMed...
    26. Bechara A, Romano S, Casabé A, Haime S, Dedola P, Hernández C, Rey H. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/ BPH. Pilot study. J Sex Med 2008; 5(9): 2170-2178. (Level 1b). Go to original source... Go to PubMed...
    27. Záleský M, Zachoval R, Vik V, Nencka P. Léčba hyperaktivity močového měchýře (OAB) u mužů. Urol List 2009; 7(2): 23-30.
    28. Giblo V, Louda M, Pacovský J. Porovnání chirurgické a farmakologické léčby inkontinence. Urol. praxi, 2011; 12(6): 366-372.
    29. Ghazal M. Farmakoterapie LUTS/BPH v každodenní klinické praxi. Jak vybrat optimální alternativu? Urol List 2013; 11(2): 12-24.
    30. Abrams P, Cardozo, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 37-49. Go to original source... Go to PubMed...
    31. Broďák M, Holub L, Košina J, Romžová M, Pacovský J, Navrátil P, Louda M. Prevalence symptomu dolních močových cest a hyperaktivního močového měchýře. Urolog. Praxi, 2008; 9(1): 16-20.
    32. Kerrebroeck F, Haab F, Angulo J, Vik V, Katona F, Carcia-Hernandez A, Klaver M, Traudtner K, Oelke M. Efficacy and Safety of Solifenacin Plus Tamsulosin OCAS in Men with Voiding and Storage Lower Urinary Tract Symptoms: Results from a Phase 2, Dose-finding Study (SATURN). European Urology 64(2013): 398-407. Go to original source... Go to PubMed...
    33. van Kerrebroeck P, Chapple C, Drogendijk T, Klaver M, Sokol R, Speakman M, Traudtner K, Drake MJ. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur. Urol. 2013 Dec: 64(6): 1003-1012. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.